Kura Oncology, Inc. (NASDAQ:KURA) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Kura Oncology, Inc. (NASDAQ:KURA) from a buy rating to a hold rating in a research report report published on Wednesday, October 18th.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

A number of other analysts have also weighed in on KURA. Oppenheimer Holdings, Inc. reiterated an outperform rating and issued a $16.00 price objective on shares of Kura Oncology in a research note on Wednesday, June 28th. Citigroup Inc. set a $13.00 price objective on shares of Kura Oncology and gave the stock a buy rating in a research note on Tuesday, August 8th. Leerink Swann reiterated an outperform rating and issued a $18.00 price objective (up previously from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. ValuEngine lowered shares of Kura Oncology from a hold rating to a sell rating in a research note on Friday, September 1st. Finally, Cowen and Company started coverage on shares of Kura Oncology in a research note on Thursday, September 7th. They issued an outperform rating on the stock. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $16.00.

Shares of Kura Oncology (NASDAQ KURA) traded down $0.15 during mid-day trading on Wednesday, reaching $14.80. The company’s stock had a trading volume of 276,355 shares, compared to its average volume of 375,567. The company has a current ratio of 10.80, a quick ratio of 10.79 and a debt-to-equity ratio of 0.16. Kura Oncology has a 12 month low of $4.00 and a 12 month high of $15.70.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.03. equities research analysts expect that Kura Oncology will post -1.54 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first posted by BBNS and is the property of of BBNS. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://baseballnewssource.com/markets/kura-oncology-inc-kura-stock-rating-lowered-by-zacks-investment-research/1722762.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Wisconsin Investment Board purchased a new stake in Kura Oncology during the second quarter worth $102,000. Oppenheimer & Co. Inc. boosted its holdings in Kura Oncology by 14.7% during the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock worth $110,000 after buying an additional 1,600 shares in the last quarter. Rhumbline Advisers purchased a new stake in Kura Oncology during the second quarter worth $131,000. Nationwide Fund Advisors purchased a new stake in Kura Oncology during the first quarter worth $136,000. Finally, New York State Common Retirement Fund purchased a new stake in Kura Oncology during the second quarter worth $142,000. 40.56% of the stock is currently owned by hedge funds and other institutional investors.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.